NASDAQ:LIFE
aTyr Pharma Stock News
$1.60
-0.0200 (-1.23%)
At Close: Apr 24, 2024
aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay S. Shukla on Q1 2022 Results - Earnings Call Transcript
09:15pm, Monday, 09'th May 2022
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. Sanjay S. Shukla – President and Chief Executive Officer Jill Broadfoot – Chief Fi
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
09:15pm, Monday, 09'th May 2022 Zacks Investment Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
06:49pm, Monday, 09'th May 2022
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
04:14pm, Thursday, 14'th Apr 2022 Zacks Investment Research
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
01:33pm, Thursday, 14'th Apr 2022
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
12:00pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
Second U.S. orphan drug designation for efzofitimod clinical program Second U.S. orphan drug designation for efzofitimod clinical program
Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect?
11:17am, Wednesday, 06'th Apr 2022
The consensus price target hints at a 235.8% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
12:00pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
08:00am, Friday, 01'st Apr 2022
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological p
Can Atyr Pharma (LIFE) Climb 266% to Reach the Level Wall Street Analysts Expect?
02:00pm, Monday, 21'st Mar 2022 Zacks Investment Research
The consensus price target hints at a 265.6% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
04:00pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
01:32pm, Thursday, 17'th Mar 2022
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
aTyr Pharma files for $200M mixed shelf offering
09:56pm, Tuesday, 15'th Mar 2022 Seeking Alpha
aTyr Pharma (LIFE) has filed for a $200M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.The company said it will use…
